Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 27, Pages 7148-7153Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1705240114
Keywords
Presenilin 1; phosphorylation; autophagy; autophagosome-lysosome fusion; Annexin A2
Categories
Funding
- Fisher Center for Alzheimer's Research Foundation
- NIH [AG047781]
- Department of Defense/US Army Medical Research Acquisition Activity (DOD/USAMRAA) [W81XWH-09-1-0402]
- JPB Grant [475]
- DOD/USAMRAA [W81XWH-14-1-0045]
- NIH/National Institute of Diabetes and Digestive and Kidney Diseases [DK098109]
- Veterans Affairs Merit Award
Ask authors/readers for more resources
Presenilin 1 (PS1), the catalytic subunit of the gamma-secretase complex, cleaves beta CTF to produce A beta. We have shown that PS1 regulates A beta levels by a unique bifunctional mechanism. In addition to its known role as the catalytic subunit of the.-secretase complex, selective phosphorylation of PS1 on Ser367 decreases A beta levels by increasing beta CTF degradation through autophagy. Here, we report the molecular mechanism by which PS1 modulates beta CTF degradation. We show that PS1 phosphorylated at Ser367, but not nonphosphorylated PS1, interacts with Annexin A2, which, in turn, interacts with the lysosomal N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) Vamp8. Annexin A2 facilitates the binding of Vamp8 to the autophagosomal SNARE Syntaxin 17 to modulate the fusion of autophagosomes with lysosomes. Thus, PS1 phosphorylated at Ser367 has an antiamyloidogenic function, promoting autophagosome-lysosome fusion and increasing beta CTF degradation. Drugs designed to increase the level of PS1 phosphorylated at Ser367 should be useful in the treatment of Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available